Literature DB >> 26655485

Ocular Surface Disease Index (OSDI) Versus the Standard Patient Evaluation of Eye Dryness (SPEED): A Study of a Nonclinical Sample.

Kofi Asiedu1, Samuel Kyei, Sekyere N Mensah, Stephen Ocansey, Listowell S Abu, Elvis A Kyere.   

Abstract

PURPOSE: To compare the Standard Patient Evaluation of Eye Dryness (SPEED) and the Ocular Surface Disease Index (OSDI) questionnaires, and to further validate the SPEED questionnaire using the OSDI in a nonclinical sample.
METHODS: This was a cross-sectional study involving 657 undergraduate students aged 18-34 years. Subject selection was by systematic random methods.
RESULTS: The Cronbach alphas of the SPEED and OSDI questionnaires were 0.895 and 0.897, respectively. Classification of participants based on OSDI grading of severity indicated that the total mean SPEED score were 2.2, 5.0, 6.6 and 9.9 for the asymptomatic, mild, moderate and severe dry eye groups respectively (F(3,653) = 141.3 P < 0.001,η=0.394). Post hoc testing for all between-group differences was statistically significant (P < 0.05; Tukey test of multiple comparisons). There was a significant correlation between the total scores of the OSDI and SPEED questionnaires (rs = 0.68 P < 0.001). The receiver operating characteristic curve (ROC) of the SPEED questionnaire was plotted, and the area under the curve (AUC) was estimated to be 0.82 (95% CL: 0.79-0.85; P < 0.001). Factor analysis revealed 3 dimensions as responsible for the substantial amount of variance in the data generated by the SPEED questionnaire.
CONCLUSIONS: The SPEED questionnaire was good in separating asymptomatic and symptomatic participants in comparison with the OSDI. This indicates that the SPEED questionnaire is a valid measure for dry eye symptoms even in a nonclinical sample and would be useful in epidemiological studies and clinical practice for dry eye symptom assessment.

Entities:  

Mesh:

Year:  2016        PMID: 26655485     DOI: 10.1097/ICO.0000000000000712

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  36 in total

1.  Meibomian gland atrophy with duration of Sjogren's syndrome in adult females.

Authors:  Sung Rae Noh; Jae Lim Chung; Jeong Min Lee; Kyoung Yul Seo; Kyungmin Koh
Journal:  Int Ophthalmol       Date:  2021-08-19       Impact factor: 2.031

2.  Reliability of Chinese web-based ocular surface disease index questionnaire in dry eye patients: a randomized, crossover study.

Authors:  Xin-Mei Zhang; Lan-Ting Yang; Qing Zhang; Qing-Xia Fan; Can Zhang; Yue You; Chen-Guang Zhang; Tie-Zhu Lin; Ling Xu; Salissou Moutari; Jonathan E Moore; Emmanuel E Pazo; Wei He
Journal:  Int J Ophthalmol       Date:  2021-06-18       Impact factor: 1.779

3.  Spatial Distribution of Noninvasive Break Up Times and Clinical Relevance in Healthy Participants and Mild Dry Eye.

Authors:  Louis Tong; Calesta Hui Yi Teo; Ryan Khee Jin Lee
Journal:  Transl Vis Sci Technol       Date:  2019-10-17       Impact factor: 3.283

4.  Prevalence of Meibomian Gland Atrophy in a Pediatric Population.

Authors:  Preeya K Gupta; Madelyn N Stevens; Namita Kashyap; Yos Priestley
Journal:  Cornea       Date:  2018-04       Impact factor: 2.651

5.  Assessment of meibomian glands using a custom-made meibographer in dry eye patients in Ghana.

Authors:  Eugene Appenteng Osae; Reynolds Kwame Ablorddepey; Jens Horstmann; David Ben Kumah; Philipp Steven
Journal:  BMC Ophthalmol       Date:  2018-08-16       Impact factor: 2.209

6.  Risk factors for severe Meibomian gland atrophy in a young adult population: A cross-sectional study.

Authors:  Thao N Yeh; Meng C Lin
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

7.  The correlation of cytokines and sensory hypersensitivity in mild dry eye patients characterized by symptoms outweighing signs.

Authors:  Bei Li; Ying Tian; Shuangyong Wang
Journal:  Mol Vis       Date:  2020-05-09       Impact factor: 2.367

8.  Comparison of efficacy of trehalose-based eye drops versus topical 0.1% Hyaluronic Acid for management of clinically significant dry eye using non-invasive investigational modalities.

Authors:  Sheetal Brar; Hemanth Reddy Vanga; Sri Ganesh
Journal:  Int Ophthalmol       Date:  2021-05-27       Impact factor: 2.031

9.  Corneal Nerve Regeneration after Self-Retained Cryopreserved Amniotic Membrane in Dry Eye Disease.

Authors:  Thomas John; Sean Tighe; Hosam Sheha; Pedram Hamrah; Zeina M Salem; Anny M S Cheng; Ming X Wang; Nathan D Rock
Journal:  J Ophthalmol       Date:  2017-08-15       Impact factor: 1.909

10.  A novel system, TearCare®, for the treatment of the signs and symptoms of dry eye disease.

Authors:  David Badawi
Journal:  Clin Ophthalmol       Date:  2018-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.